5 vs 10-Minute Chewing of Caffeinated Gum: Plasma Caffeine Pharmacokinetics

NCT07386899 — Not applicable, Completed, 30 participants, Ege University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Optimizing the Timing of Caffeinated Gum: Effects of 5- and 10-Minute Chewing on Plasma Caffeine Pharmacokinetics in Healthy Men

RegistryNCT07386899
StatusCompleted
PhaseNot applicable
Study typeInterventional; non randomized, crossover, masking: none, basic science
Enrollment30 (Actual)
SponsorEge University (Other); collaborators: The Scientific and Technological Research Council of Turkey
ConditionsCaffeine
InterventionsCaffeine 300 MG (Dietary supplement)
Datesstart 2025-04-22, primary completion 2025-06-14, completion 2025-06-14, first posted 2026-02-04, last updated 2026-02-04
Locations1 site in Turkey (Türkiye)

Related Papers Related Patents Related Grants Related Experts
All trials for Caffeine All trials of Caffeine 300 MG

-Summary

The goal of this study is to understand how chewing duration affects how quickly caffeine from caffeinated chewing gum appears in the blood and how long higher caffeine levels are maintained. The study compares two chewing durations (5 minutes and 10 minutes) in healthy men.

Each participant attends two study visits on separate days at least 48 hours apart and completes both chewing conditions. At each visit, participants chew caffeinated gum that provides approximately 300 mg of caffeine. Blood samples are collected before chewing and at several time points for up to 3 hours after chewing to measure plasma caffeine levels.

Researchers will compare the two chewing durations to determine whether chewing time changes peak plasma caffeine concentration, the time to reach the peak, overall exposure over 0 to 180 minutes, and the time that plasma caffeine remains near the peak level. The results may help guide practical timing of caffeinated gum use.

Expand all sections  ·  Collapse all

+Detailed description

This is a within-subject, repeated-measures, two-visit, fixed-sequence study comparing two chewing durations of caffeinated gum (5 minutes vs 10 minutes). Participants attend two visits on separate days with at least 48 hours between visits to minimize carryover effects. The order is fixed: the 5-minute chewing condition is completed at Visit 1 and the 10-minute chewing condition at Visit 2.

At each visit, participants receive approximately 300 mg of caffeine via commercially available caffeinated chewing gum (three pieces; about 100 mg per piece). Venous blood samples are collected to measure plasma caffeine concentration over time. Samples are obtained at baseline (0 minutes), during chewing (5 minutes in both conditions and 10 minutes only in the 10-minute condition), and after chewing at 30, 50, 60, 80, 90, 120, and 180 minutes. Plasma caffeine is quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

The plasma caffeine concentration-time profile is used to derive pharmacokinetic outcomes, including peak plasma caffeine concentration, time to peak concentration, exposure from 0 to 180 minutes, and the duration that plasma caffeine remains at or above 90% and 80% of the individual peak concentration.

The study was approved by the Ege University Faculty of Medicine Medical Research Ethics Committee, and written informed consent was obtained from all participants prior to participation.

+Arms and interventions

ArmTypeInterventionsDescription
5-Minute ChewingExperimentalDietary Supplement: Caffeine 300 MGParticipants chew caffeinated chewing gum for 5 minutes (total caffeine approximately 300 mg).
10-Minute ChewingExperimentalDietary Supplement: Caffeine 300 MGParticipants chew caffeinated chewing gum for 10 minutes (total caffeine approximately 300 mg).
  • Caffeine 300 MG (Dietary supplement): 300 mg (three pieces; \~100 mg each) administered at each visit. Participants chew for 5 minutes in one condition and 10 minutes in the other condition.

+Outcome measures

Primary outcomes

  • Peak Plasma Caffeine Concentration (Cpeak) [From baseline (0 minutes) up to 180 minutes post-chewing]: Highest observed plasma caffeine concentration over the 0-180 minute sampling period, quantified from venous blood samples analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Unit: µg/mL.
  • Time to Peak Plasma Caffeine Concentration (Tpeak) [From baseline (0 minutes) up to 180 minutes post-chewing]: Time (minutes) from baseline (start of sampling) to the individual peak plasma caffeine concentration (Cpeak) within the 0-180 minute sampling period.
  • Area Under the Plasma Caffeine Concentration-Time Curve From 0 to 180 Minutes (AUC0-180) [0 to 180 minutes post-chewing]: Total plasma caffeine exposure from 0 to 180 minutes calculated from measured plasma caffeine concentrations (trapezoidal method). Unit:mg·h/L.

Secondary outcomes

  • Duration Plasma Caffeine Remains at or Above 90% of Individual Peak (Sustain90) [0 to 180 minutes post-chewing]: Duration (minutes) during which plasma caffeine concentration is at or above 90% of the individual Cpeak within the 0-180 minute sampling period.
  • Duration Plasma Caffeine Remains at or Above 80% of Individual Peak (Sustain80) [0 to 180 minutes post-chewing]: Duration (minutes) during which plasma caffeine concentration is at or above 80% of the individual Cpeak within the 0-180 minute sampling period.
  • Plasma Caffeine Concentration-Time Profile [Baseline (0 minutes) through 180 minutes post-chewing]: Plasma caffeine concentrations (µg/mL) measured at prespecified time points: 0, 5, 10 (10-minute condition only), 30, 50, 60, 80, 90, 120, and 180 minutes post-chewing, analyzed by LC-MS/MS.

+Eligibility

Sex: Male, ages: 18 Years to 35 Years, accepts healthy volunteers

Inclusion Criteria:

* Male, 18-35 years
* Good general health
* No regular use of medications or substances
* Habitual daily caffeine intake ≤300 mg/day

Exclusion Criteria:

* Habitual daily caffeine intake >300 mg/day
* Failure to participate in any study measurements
* Failure to comply with required test and measurement protocols
* Experiencing adverse effects from caffeine during the compliance period

+Locations (1)

FacilityCityCountryStatus
Ege University, Faculty of Sport SciencesIzmir, BornovaTurkey (Türkiye)

+Publications

  • Results publication: Kamimori GH, Karyekar CS, Otterstetter R, Cox DS, Balkin TJ, Belenky GL, Eddington ND. The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int J Pharm. 2002 Mar 2;234(1-2):159-67. doi: 10.1016/s0378-5173(01)00958-9. PMID 11839447

+Investigators

  • Hakan Arslan, Dr., Principal investigator, Ege University
  • Gülbin Rudarlı, professor, Study chair, Ege University